Publications

Lenvatinib (L) Versus Sorafenib (S) Second-Line Therapy in Hepatocellular Carcinoma (Hcc) Patients (P) Progressed to Atezolizumab plus Bevacizumab (Ab)

AuthID
P-017-5PF

Author(s)

Persano, M

Rimini, M

Foti, S

Camera, S

Rossari, F

Amadeo, E

Vitiello, F

Tada, T

Suda, G

Shimose, S

Kudo, M

Yoo, C

Cheon, J

Finkelmeier, F

Lim, HY

Presa, J

Mascia, L

Cascinu, S

Scartozzi, M

Gardini, AC

Document Type

Abstract

Year published

2024

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 35, Pages: S83-S83 (1)

Conference

Gastrointestinal Cancers Congress of the European-Society-For-Medical-Oncology (Esmo), Date: JUN 26-29, 2024, Location: Munich, GERMANY

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2024.05.193

Wos: WOS:001299993900183

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Lenvatinib (L) Versus Sorafenib (S) Second-Line Therapy in Hepatocellular Carcinoma (Hcc) Patients (P) Progressed to Atezolizumab plus Bevacizumab (Ab)

Useful Links

Get Help

Federated Authentication (Click on the image)

Lenvatinib (L) Versus Sorafenib (S) Second-Line Therapy in Hepatocellular Carcinoma (Hcc) Patients (P) Progressed to Atezolizumab plus Bevacizumab (Ab)

Useful Links

Get Help